- Geron Corporation (GERN, Financial) presents new data highlighting the efficacy and safety of RYTELO® (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) at ASCO and EHA 2025.
- The presentations underscore RYTELO's potential for transfusion independence across various LR-MDS patient subgroups.
- Updated trial data on imetelstat in myelofibrosis (MF) shows promising progress in ongoing clinical trials.
Geron Corporation (GERN) has showcased new findings on its first-in-class telomerase inhibitor, RYTELO®, at the 2025 meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). The data, derived from post-hoc analyses of the IMerge trial, emphasize RYTELO's potential benefits in patients with lower-risk myelodysplastic syndromes (LR-MDS) who suffer from transfusion-dependent anemia.
Notably, RYTELO demonstrated clinical benefits regardless of patients' ring sideroblast status, baseline serum erythropoietin (sEPO) levels, or previous therapies. This positions RYTELO as a promising treatment option for broad patient segments, including those ineligible for erythropoiesis-stimulating agents (ESAs) or who have failed prior treatments.
Health-related quality-of-life improvements and increased duration without transfusion dependence were observed in RYTELO-treated patients, providing new insights into patient-centric outcomes in LR-MDS. The ongoing IMpactMF and IMproveMF trials of imetelstat in myelofibrosis (MF) were also highlighted, revealing that the combination of imetelstat with ruxolitinib was well-tolerated with encouraging efficacy signals.
Dr. Faye Feller, Chief Medical Officer of Geron, stated that these findings reinforce RYTELO's potential to meet critical unmet needs in LR-MDS, positioning it as an important asset in the treatment landscape.
With these advancements, Geron remains committed to fully exploring the clinical potential of telomerase inhibition in hematologic malignancies, ensuring that therapies like RYTELO continue to change lives by altering the trajectory of serious blood cancers.
